BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27263854)

  • 21. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.
    Owecki M; Sowiński J
    Pharm World Sci; 2006 Apr; 28(2):73-5. PubMed ID: 16791713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?
    Bartalena L
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):149-52. PubMed ID: 20148907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.
    Leo M; Mautone T; Ionni I; Profilo MA; Sabini E; Menconi F; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    Endocr Pract; 2016 Oct; 22(10):1177-1186. PubMed ID: 27732097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Steroid therapy for Graves' ophthalmopathy].
    Hiromatsu Y
    Nihon Rinsho; 2006 Dec; 64(12):2279-85. PubMed ID: 17154092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
    Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
    Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
    Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucocorticoid regimens for prevention of Graves' ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis.
    Shiber S; Stiebel-Kalish H; Shimon I; Grossman A; Robenshtok E
    Thyroid; 2014 Oct; 24(10):1515-23. PubMed ID: 25068172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relevance of serum immunoglobulin G4 in glucocorticoid therapy of Graves' ophthalmopathy.
    Li Y; Luo B; Zhang J; Zhou X; Shao S; Xu W; Yang Y; Yuan G
    Clin Endocrinol (Oxf); 2021 Oct; 95(4):657-667. PubMed ID: 33938028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
    Sawicka-Gutaj N; Gruszczyński D; Zawalna N; Nijakowski K; Skiba A; Pochylski M; Sowiński J; Ruchała M
    Pharmacol Rep; 2024 Feb; 76(1):185-194. PubMed ID: 38273183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?
    Bartalena L; Veronesi G; Krassas GE; Wiersinga WM; Marcocci C; Marinò M; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G; Perros P; Kahaly GJ;
    J Endocrinol Invest; 2017 May; 40(5):547-553. PubMed ID: 28176220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves' ophthalmopathy.
    Shen L; Huang F; Ye L; Zhu W; Zhang X; Wang S; Wang W; Ning G
    Endocrine; 2015 Jun; 49(2):445-56. PubMed ID: 25588771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study.
    Lai A; Sassi L; Compri E; Marino F; Sivelli P; Piantanida E; Tanda ML; Bartalena L
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1333-7. PubMed ID: 20061414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three dimensional orbital magnetic resonance T2-mapping in the evaluation of patients with Graves' ophthalmopathy.
    Hou K; Ai T; Hu WK; Luo B; Wu YP; Liu R
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):938-942. PubMed ID: 29270757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
    Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
    Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves' Orbitopathy.
    Oeverhaus M; Witteler T; Lax H; Esser J; Führer D; Eckstein A
    Horm Metab Res; 2017 Oct; 49(10):739-747. PubMed ID: 28922676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
    Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
    Brauer VF; Scholz GH
    Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study.
    Sisti E; Coco B; Menconi F; Leo M; Rocchi R; Latrofa F; Profilo MA; Mazzi B; Albano E; Vitti P; Marcocci C; Brunetto M; Marinò M
    Eur J Endocrinol; 2015 Mar; 172(3):269-76. PubMed ID: 25661744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.